← All trials
NCT06018337
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Aug 31, 2025
- Completion date
- Jun 30, 2027
- First posted
- Aug 30, 2023
- Last posted
- Dec 14, 2023
- Enrollment
- 532
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DualityBio Inc.Lead sponsor
- DualityBio Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.